New infusion drug aims to help MASH cirrhosis patients
NCT ID NCT07325526
First seen Jan 11, 2026
Summary
This study tests a new medicine called BI 3802876 in 29 adults with compensated cirrhosis caused by MASH, a type of fatty liver disease. Participants receive either the drug or a placebo as an infusion, and researchers monitor safety and how the body processes the drug over about six months. The goal is to see if the drug is well-tolerated and may improve liver health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Research Corporation at the Texas Liver Institute
RECRUITINGSan Antonio, Texas, 78215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Arizona Clinical Trials - Chandler
NOT_YET_RECRUITINGChandler, Arizona, 85225, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Baylor Scott & White Research Institute
NOT_YET_RECRUITINGDallas, Texas, 75246, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Catalina Research Institute, LLC
NOT_YET_RECRUITINGMontclair, California, 91763, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centricity Research Columbus Georgia Multispecialty
NOT_YET_RECRUITINGColumbus, Georgia, 31904, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Columbia University Medical Center
NOT_YET_RECRUITINGNew York, New York, 10032, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Covenant Metabolic Specialists, LLC - University Park
NOT_YET_RECRUITINGUniversity Park, Florida, 34201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Epic Medical Research - Carrollton
NOT_YET_RECRUITINGCarrollton, Texas, 75006, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Epic Medical Research - Fort Worth
NOT_YET_RECRUITINGFort Worth, Texas, 76120, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Houston Methodist Hospital
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Johns Hopkins Hospital
NOT_YET_RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kaiser Permanente - Los Angeles Medical Center
NOT_YET_RECRUITINGLos Angeles, California, 90027, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lucas Research, Inc.
NOT_YET_RECRUITINGMorehead City, North Carolina, 28557, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic, Rochester
NOT_YET_RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Medical University of South Carolina
NOT_YET_RECRUITINGCharleston, South Carolina, 29425, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nashville General Hospital
NOT_YET_RECRUITINGNashville, Tennessee, 37209, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Panax Clinical Research
NOT_YET_RECRUITINGMiami Lakes, Florida, 33014, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peak Gastroenterology Associates
NOT_YET_RECRUITINGColorado Springs, Colorado, 80907, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Pioneer Research Solutions, Inc.
NOT_YET_RECRUITINGHouston, Texas, 77099, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Schiff Center Liver Diseases
NOT_YET_RECRUITINGMiami, Florida, 33136, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Southern California Research Center
NOT_YET_RECRUITINGCoronado, California, 92118, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Texas Clinical Research Institute, LLC
NOT_YET_RECRUITINGArlington, Texas, 76012, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Liver Institute at Methodist Dallas
NOT_YET_RECRUITINGDallas, Texas, 75203, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Alberta Hospital (University of Alberta)
NOT_YET_RECRUITINGEdmonton, Alberta, T6G 2XB, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Iowa Hospitals and Clinics
NOT_YET_RECRUITINGIowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Kansas Medical Center
NOT_YET_RECRUITINGKansas City, Kansas, 66160, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Velocity Clinical Research, San Diego
NOT_YET_RECRUITINGLa Mesa, California, 91942, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI 3802876 (given as an infusion into a vein)
What this could lead to
If successful, this could point toward a treatment to improve liver health in people with MASH-related cirrhosis.
What could go wrong
This is an early Phase 2 trial with only 29 participants, so results may not apply to everyone. The main goal is safety, not yet effectiveness, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.